IMNM Immunome, Inc.
XNAS
18.82
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IMNM
$18.82
—
Key stats
$18.82
- 52-Week Range
- $14.64 – $30.06
- YTD
- -9.63%
- IV Rank (30D)
- 62.63
- Straddle Price
- $4.45
- P/C Vol Ratio
- 0.86
- Market Cap
- $2.1B
- Open
- $18.21
- Day Range
- $17.32 – $18.96
- Volume
- 866,657
- Prev Close
- $17.91
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.95% |
| Beta vs SPY | 1.48 |
| Cost of Equity (CAPM) | 13.08% (VRP-adj) |
| WACC | 13.14% |
| Volatility Risk Premium | +49.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -48.4% |
| Book / Price | 28.7% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $21.69 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $18.28 |
| Bollinger Width / SMA20 | 116.1% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $2B |
Peers used for multiples: CELC, COGT, EXEL, JNJ, LLY, MRK, NUVL, RVMD
60-Day Conviction
91%
20-Day Fair Value
≈ by Dec 7, 2026
$18.70
α +0.1%
rank 77%
conviction
4%
40-Day Fair Value
≈ by Jan 5, 2027
$19.21
α +2.8%
rank 77%
conviction
84%
60-Day Fair Value
≈ by Feb 3, 2027
$19.49
α +4.3%
rank 75%
conviction
91%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 43.6× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 24.5× · 4 peers |
| Peer P/B | $49.66 | 14% | median 9.7× · 7 peers |
| Peer P/S | n/a | 0% | median 6.9× · 4 peers |
| Market Anchor (SMA50) | $21.69 | 50% | stability 70% (BB-width) |
| Options Expected (B-L 30d) | $17.29 | 36% | 23 strikes · skew +0.18 |
As of 2026-11-06 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.1B
- Employees
- 177
- List Date
- 2020-10-02
- CIK
- 0001472012
- Headquarters
- Bothell, WA
- Homepage
- https://www.immunome.com
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance an…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 49.03% | -35.95% | 62.27% | 50.50% | 4.75% | 18.25% | 24.81% |
| Feb | 129.98% | -27.05% | -13.12% | 47.11% | -8.91% | -16.37% | 18.61% |
| Mar | -15.19% | -9.84% | 9.91% | -3.03% | -24.72% | -1.53% | -7.40% |
| Apr | -17.85% | -35.06% | 1.38% | -36.41% | 40.42% | 2.18% | -7.56% |
| May | -16.52% | 1.30% | 4.38% | 1.70% | -1.13% | -3.96% | -2.37% |
| Jun | -15.94% | -11.33% | 45.94% | -17.07% | 2.65% | 1.97% | 1.04% |
| Jul | -5.15% | 14.60% | -10.61% | 26.31% | 24.28% | 5.42% | 9.14% |
| Aug | -11.03% | 53.07% | -11.03% | 0.73% | -10.20% | 19.12% | 6.78% |
| Sep | 62.99% | -22.11% | 27.68% | 4.13% | 26.19% | -20.52% | 13.06% |
| Oct | 16.27% | -8.98% | 7.32% | -15.16% | 41.71% | -12.83% | 4.72% |
| Nov | -14.91% | -1.70% | -12.95% | 16.91% | 8.35% | -4.80%* | -1.52% |
| Dec | -27.35% | -50.67% | 37.18% | -24.57% | 17.25% | -- | -9.63% |
| Total | 65.66% | -85.18% | 211.41% | 14.13% | 159.54% | -19.29% | 57.71% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $18.24
SMA 50: $21.49
SMA 200: $22.37
Current: $18.80
EMA 12: $18.77
EMA 26: $19.34
MACD: -0.5670 | Signal: 0.3147
BEARISH
ADX (14): 27.15
TREND
+DI: 25.71
−DI: 18.13
Momentum Oscillators
RSI (14): 46.48
NEUTRAL
Stoch %K: 36.05
Stoch %D: 57.53
Williams %R: -63.91
Volume & Volatility
BB Upper: $20.11
BB Lower: $16.37
NEUTRAL
OBV: 47,663,159
Vol SMA 20: 1,541,929
Vol ROC: -40.66%
ATR: $1.36
True Range: $1.64
HV 20: 70.5%
HV 30: 64.2%
HV 60: 59.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-05T00:00:00
AI Analysis
LLM Stock Analysis Report: IMNM
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers: Bullish technical signals, positive news sentiment, and relatively low volatility.
Primary risks: High beta, potential for high volatility, and negative earnings surprise.
Investment thesis: IMNM has strong technical momentum, with MACD indicating a bullish signal. The recent news headlines are generally positive, which supports the stock's price movement. However, the high beta and historical volatility warrant caution.
Recent news sentiment impact: Positive news sentiment from Immunome's Chief Scientist trimming his stake and planned FDA submission had a significant impact on the stock's price movement.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Neutral
Support/Resistance Levels: SMA 20: $23.26 (support), Upper Bollinger Band: $25.75 (resistance)
Momentum Signals:
- RSI interpretation: Neutral (68.34)
- MACD signal: Bullish
- Bollinger Bands position: Neutral
Volume Analysis: Volume SMA 20: 1020458.70, On-Balance Volume (OBV): 43697946.71, Volume Rate of Change: 99.72%
News & Sentiment Analysis
Recent Headlines Summary: Positive news sentiment from Immunome's Chief Scientist trimming his stake and planned FDA submission.
Sentiment Assessment: Positive (4/5 headlines)
Catalyst Identification: Planned FDA submission, potential for positive earnings surprise
Market Narrative: The recent news headlines support the stock's price movement, indicating a bullish market narrative.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock with beta >1.5
Volatility Regime: Current volatility is relatively low compared to historical levels
Options Market Signals: IV rank: 15.0% (Low), Put/Call Volume Ratio: 0.36 (Bullish sentiment)
Downside Protection: Support at SMA 20 ($23.26) and Bollinger Band lower ($20.77)
Market Context & Positioning
Sector Performance: Immunome's sector, Biotechnology, has been performing relatively well in the short term
Institutional Activity: No significant institutional activity noted
Correlation Analysis: IMNM is highly correlated with the market (R-squared interpretation: 0.88)
Relative Valuation: The stock is trading within its historical range
Key Levels & Action Items
Critical Price Levels: SMA 20 ($23.26), Upper Bollinger Band ($25.75), and Lower Bollinger Band ($20.77) are key levels to monitor
Breakout/Breakdown Levels: If IMNM breaks above the Upper Bollinger Band, it could trigger a significant move
Time-Sensitive Catalysts: Upcoming FDA submission and potential earnings surprise
Risk Management: Consider stop-loss levels at SMA 20 ($23.26) and position sizing considerations given the high beta.
Note: This report is intended to provide a comprehensive analysis of IMNM's technical, news, and risk metrics. It does not contain buy or sell advice.
Generated
News
All IMNM news →
Earnings History
17 of 17 under expected move
Avg Expected Move
24.24%
Avg Actual Move
3.57%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-03-28 | After-Close | 32.04% | 0.84% | 0.03x | Within |
| 2022-11-14 | After-Close | 55.02% | 0.60% | 0.01x | Within |
| 2023-05-05 | After-Close | 15.93% | 6.67% | 0.42x | Within |
| 2023-08-09 | After-Close | 13.92% | 0.14% | 0.01x | Within |
| 2023-11-09 | After-Close | 17.99% | 5.49% | 0.31x | Within |
| 2024-02-13 | After-Close | 10.41% | 2.90% | 0.28x | Within |
| 2024-05-14 | After-Close | 16.64% | 0.54% | 0.03x | Within |
| 2024-08-12 | After-Close | 17.01% | 7.04% | 0.41x | Within |
| 2024-11-13 | After-Close | 22.43% | 3.88% | 0.17x | Within |
| 2025-01-29 | After-Close | 52.94% | 12.41% | 0.23x | Within |
| 2025-03-19 | After-Close | 40.26% | 1.05% | 0.03x | Within |
| 2025-05-12 | After-Close | 23.93% | 0.38% | 0.02x | Within |
| 2025-08-06 | After-Close | 13.38% | 5.64% | 0.42x | Within |
| 2025-11-06 | After-Close | 43.71% | 1.68% | 0.04x | Within |
| 2026-03-03 | After-Close | 11.37% | 4.55% | 0.40x | Within |
| 2026-05-11 | After-Close | 6.74% | 1.35% | 0.20x | Within |
| 2026-08-12 | After-Close | 18.31% | 5.61% | 0.31x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
IMNM Options Activity & IV Rank
IMNM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 104.6%
7-DTE IV: 157.6%
Expected Move: $4.45
7-DTE Move: $3.88
Days to Exp: 42 (2026-12-18)
Options Flow
Call Volume: 622
Put Volume: 537
P/C Volume: 0.863
NEUTRAL
Call OI: 1,881
Put OI: 622
P/C OI: 0.331
Total OI: 2,503
ATM Options Pricing
ATM Call: $2.45
ATM Put: $2.00
Call %: 13.0%
Put %: 10.6%
Chain Summary
Chain Volume: 8,249
Chain OI: 11,492
Last Updated: 11/6/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 50th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
50%
vs own history
GEX tilt
+0.33
OI-weighted, today
Vanna tilt
+0.00
δ-sensitivity to IV
Charm tilt
+0.15
δ-decay vs time
? What is this?
· 22 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM 90.5% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)35.8MediumNov 6
IV Rank (30 DTE)62.6MediumNov 6
Straddle Price (30 DTE)$4.45Nov 6
Beta Analysis
Risk Metrics
Beta: 1.5360
Alpha: 21.05%
Correlation: 0.3390
R-Squared: 11.5%
Stock Volatility: 61.5%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own IMNM
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $5.3M | #1427 of 3138 | +264.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $4.7M | #2136 of 6285 | +179.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $0K | #4691 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
IMNM Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 102,348,123 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$7.17M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.39M | 47.24% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.98M | 27.62% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.23M | 17.13% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $531.87K | 7.42% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $42.38K | 0.59% | 2026-06-30 |
5 filers$2.09M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $983.22K | 47.06% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $491.61K | 23.53% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $449.23K | 21.50% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $127.14K | 6.09% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $38.14K | 1.83% | 2026-06-30 |
IMNM Insider Trading (Form 4)
Latest: 2026-09-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Jack Higgins | Chief Scientific Officer | Mixed | −4,000 | $11.49 | -$309.9K | EDGAR |
| 2026-08-12 | Isaac Barchas | Director | Sell (S) | −83,464 | $26.35 | -$2.20M | EDGAR |
| 2026-08-10 | Isaac Barchas | Director | Sell (S) | −36,088 | $26.06 | -$940.5K | EDGAR |
| 2026-08-06 | Kinney Horn | CHIEF BUSINESS OFFICER | Mixed | — | $18.49 | -$1.20M | EDGAR |
| 2026-07-27 | Max Rosett | Chief Financial Officer | Award (A) | +47,250 | — | EDGAR | |
| 2026-07-27 | Philip Tsai | Chief Technical Officer | Award (A) | +38,250 | — | EDGAR | |
| 2026-07-27 | Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | Award (A) | +38,250 | — | EDGAR | |
| 2026-07-27 | Clay B Siegall | President and CEO | Award (A) | +180,000 | — | EDGAR | |
| 2026-07-27 | Kinney Horn | CHIEF BUSINESS OFFICER | Award (A) | +31,250 | — | EDGAR | |
| 2026-07-27 | Robert Lechleider | Chief Medical Officer | Award (A) | +54,000 | — | EDGAR | |
| 2026-07-27 | Jack Higgins | Chief Scientific Officer | Award (A) | +38,250 | — | EDGAR | |
| 2026-07-09 | Kinney Horn | CHIEF BUSINESS OFFICER | Mixed | — | $18.96 | -$13.2K | EDGAR |
| 2026-07-07 | Robert Lechleider | Chief Medical Officer | Mixed | — | $15.68 | -$764.2K | EDGAR |
| 2026-07-07 | Isaac Barchas | Director | Sell (S) | −100,000 | $24.13 | -$2.41M | EDGAR |
| 2026-07-02 | Isaac Barchas | Director | Sell (S) | −201,050 | $21.85 | -$4.39M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
IMNM Insider Holdings
10 insiders · @ $18.80
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Clay B Siegall | President and CEO | 870,704 | $16.36M | $6.76M | 11 | 2026-07-27 |
| 2 | Philip Wagenheim | Director | 341,147 | $6.41M | -$1.09M | 10 | 2026-06-12 |
| 3 | Isaac Barchas | Director | 154,502 | $2.90M | -$18.27M | 9 | 2026-08-12 |
| 4 | Max Rosett | Chief Financial Officer | 101,287 | $1.90M | -$2.75M | 8 | 2026-07-27 |
| 5 | Kinney Horn | CHIEF BUSINESS OFFICER | 90,616 | $1.70M | -$2.30M | 6 | 2026-08-06 |
| 6 | Philip Tsai | Chief Technical Officer | 81,550 | $1.53M | $506.5K | 6 | 2026-07-27 |
| 7 | Robert Lechleider | Chief Medical Officer | 69,805 | $1.31M | -$2.19M | 7 | 2026-07-27 |
| 8 | Jack Higgins | Chief Scientific Officer | 66,050 | $1.24M | -$587.5K | 11 | 2026-09-15 |
| 9 | Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 43,805 | $823.3K | $0 | 8 | 2026-07-27 |
| 10 | Jean Jacques Bienaime | Director | 38,915 | $731.4K | $437.4K | 12 | 2026-06-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
IMNM Board & Officers
As of SEC filings through Sep 15, 2026Directors 7
- Philip Wagenheim · since Oct 1, 2020
- Clay B Siegall · since Oct 2, 2023
- Isaac Barchas · since Oct 2, 2023
- James P Boylan · since Oct 2, 2023
- Jean Jacques Bienaime · since Nov 7, 2023
- Carol Schafer · since Jan 2, 2024
- Sandra M Swain · since Apr 25, 2024
Officers 7
- Clay B Siegall · President and CEO · since Oct 2, 2023
- Max Rosett · Chief Financial Officer · listed since Sep 2024
- Sandra G. Stoneman · Chief Legal Officer & GC · listed since Jun 2021
- Jack Higgins · Chief Scientific Officer · since Oct 2, 2023
- Robert Lechleider · Chief Medical Officer · since Oct 16, 2023
- Kinney Horn · Chief Business Officer · since Feb 12, 2024
- Philip Tsai · Chief Technical Officer · listed since Jul 2025
Changes in the last 10 years (47)
| Jul 31, 2025 | Philip Tsai listed as Chief Technical Officer (previously Chief Technology Officer) in SEC filings |
| Sep 20, 2024 | Max Rosett listed as Chief Financial Officer (previously EVP, Operations & CFO) in SEC filings |
| Jun 17, 2024 | Philip Tsai became Chief Technology Officer |
| May 17, 2024 | Max Rosett listed as EVP, Operations & CFO (previously SVP Operations) in SEC filings |
| Apr 25, 2024 | Sandra M Swain became a director |
| Apr 24, 2024 | The company announced the departure of Bob Lapetina as PAO and VP Finance & Corporate in an SEC filing |
| Feb 12, 2024 | Kinney Horn became Chief Business Officer |
| Jan 2, 2024 | Carol Schafer became a director |
| Jan 2, 2024 | Bob Lapetina became PAO and VP Finance & Corporate |
| Dec 22, 2023 | The company announced the departure of Corleen M. Roche as Chief Financial Officer in an SEC filing |
| Dec 8, 2023 | Phil Noland Roberts became Chief Technology Officer |
| Nov 7, 2023 | Jean Jacques Bienaime became a director |
| Oct 16, 2023 | Robert Lechleider became Chief Medical Officer |
| Oct 3, 2023 | Michael Rapp reported in an SEC filing no longer being a director |
| Oct 2, 2023 | Max Rosett became SVP Operations |
| Oct 2, 2023 | James P Boylan became a director |
| Oct 2, 2023 | Jack Higgins became Chief Scientific Officer |
| Oct 2, 2023 | Isaac Barchas became a director |
| Oct 2, 2023 | Clay B Siegall became a director |
| Oct 2, 2023 | Clay B Siegall became President and CEO |
| Oct 2, 2023 | Bruce Turner became Chief Strategy Officer |
| Sep 29, 2023 | The company announced the departure of Richard A Baron from the board in an SEC filing |
| Sep 29, 2023 | The company announced the departure of Purnanand D Sarma from the board in an SEC filing |
| Sep 29, 2023 | The company announced the departure of Purnanand D Sarma as President and CEO in an SEC filing |
| Sep 29, 2023 | The company announced the departure of Michael Lefenfeld from the board in an SEC filing |
| Sep 29, 2023 | The company announced the departure of John L Lamattina from the board in an SEC filing |
| Sep 29, 2023 | The company announced the departure of Dennis H Giesing as Chief Development Officer in an SEC filing |
| Jun 15, 2022 | Matthew K Robinson became Chief Technology Officer |
| Jun 16, 2021 | Franklyn G Prendergast became a director |
| Jun 1, 2021 | Sandra G. Stoneman listed as Chief Legal Officer & GC (previously Chief Legal Officer & Gen Coun) in SEC filings |
| May 26, 2021 | Michael Rapp no longer listed as a 10% owner in SEC filings |
| Apr 19, 2021 | Corleen M. Roche became Chief Financial Officer |
| Mar 23, 2021 | Dennis H Giesing became Chief Development Officer |
| Nov 30, 2020 | Diane M Marcou became Interim CFO |
| Nov 5, 2020 | Michael Rapp first listed as a 10% owner in an SEC filing |
| Oct 26, 2020 | Sandra G. Stoneman became Chief Legal Officer & Gen Coun |
| Oct 1, 2020 | Richard F Fitzgerald became Chief Financial Officer |
| Oct 1, 2020 | Richard A Baron became a director |
| Oct 1, 2020 | Purnanand D Sarma became a director |
| Oct 1, 2020 | Purnanand D Sarma became President and CEO |
| Oct 1, 2020 | Philip Wagenheim became a director |
| Oct 1, 2020 | Michael Widlitz became a director |
| Oct 1, 2020 | Michael Rapp became a director |
| Oct 1, 2020 | Michael Morin became Chief Scientific Officer |
| Oct 1, 2020 | Michael Lefenfeld became a director |
| Oct 1, 2020 | John L Lamattina became a director |
| Oct 1, 2020 | I Wistar Morris III became a 10% owner |
Not reported recently (9)
- Bruce Turner · Last reported as Chief Strategy Officer in an SEC filing dated Aug 13, 2024
- Phil Noland Roberts · Last reported as Chief Technology Officer in an SEC filing dated Dec 15, 2023
- Franklyn G Prendergast · Last reported as a director in an SEC filing dated Oct 4, 2023
- Matthew K Robinson · Last reported as Chief Technology Officer in an SEC filing dated Jun 12, 2023
- Michael Widlitz · Last reported as a director in an SEC filing dated Jun 1, 2021
- Diane M Marcou · Last reported as Interim CFO in an SEC filing dated Dec 10, 2020
- I Wistar Morris III · Last reported as a 10% owner in an SEC filing dated Oct 8, 2020
- Richard F Fitzgerald · Last reported as Chief Financial Officer in an SEC filing dated Oct 5, 2020
- Michael Morin · Last reported as Chief Scientific Officer in an SEC filing dated Oct 1, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
IMNM Proposed Insider Sales (Form 144)
Latest: 2026-09-11
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
4 filings
· $5.7M notice value
· 4 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
ABHMC II, LLC (1, $2.8M) · Horn Kinney (1, $2.3M) · Higgins Jack (1, $334K) · Barchas Isaac (1, $301K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-11 | Higgins Jack | Officer | 13,200 | $334.2K | 2026-09-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-12 | Barchas Isaac | Director | 11,048 | $301.1K | 2026-08-12 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-06 | ABHMC II, LLC | Shareholder | 108,504 | $2.77M | 2026-08-06 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-08-04 | Horn Kinney | Officer | 90,616 | $2.27M | 2026-08-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-07-07 | Horn Kinney | Officer | 1,092 | $27.3K | 2026-07-07 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-07-06 | ABHMC II, LLC | Shareholder | 100,000 | $2.36M | 2026-07-06 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-02 | Lechleider Robert | Officer | 55,000 | $1.19M | 2026-07-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-07-02 | ABHMC II, LLC | Shareholder | 100,000 | $2.15M | 2026-07-02 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-30 | ABHMC II, LLC | Shareholder | 100,000 | $2.10M | 2026-06-30 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-30 | Arsenal Bridge Venture II-B, LLC | Shareholder | 1,050 | $22.1K | 2026-06-30 | Merrill Lynch | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-11 | 0001193125-26-344636 | EDGAR |
ETF Holders
61 ETFs hold IMNM
25 shown · $279.59M total exposure · 0.05% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $75.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.07% | $53.8M | $75.4B | 2026-11-04 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.37% | $39.9M | $10.9B | 2026-11-04 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $27.6M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.14% | $19.4M | $13.4B | 2026-11-04 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $13.2M | — | 2026-09-30 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.8M | — | 2026-05-31 |
| 8 | CANC Tema Oncology ETF | Nport | 3.00% | $6.3M | — | 2026-08-31 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.3M | — | 2026-09-30 |
| 10 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.59% | $3.8M | — | 2026-08-31 |
| 11 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $3.1M | $92.8B | 2026-11-04 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $3.1M | — | 2026-11-04 |
| 13 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.15% | $2.5M | — | 2026-09-30 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.9M | — | 2026-11-04 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $1.7M | — | 2026-11-04 |
| 16 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.25% | $1.7M | — | 2026-11-05 |
| 17 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.11% | $1.5M | $1.4B | 2026-11-04 |
| 18 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $1.3M | — | 2026-05-31 |
| 19 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.05% | $1.3M | $2.7B | 2026-11-04 |
| 20 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $972,857 | $4.1B | 2026-11-04 |
| 21 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.26% | $959,021 | — | 2026-08-31 |
| 22 | DFUS Dimensional US Equity Market ETF | Dimensional | 0.00% | $932,178 | $20.8B | 2026-11-04 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.07% | $901,767 | — | 2026-11-05 |
| 24 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.05% | $765,828 | $1.4B | 2026-11-04 |
| 25 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.06% | $687,846 | $1.1B | 2026-11-04 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.52
TTM Revenue
$0.00
TTM Net Income
$-254.32M
TTM Op. Cash Flow
$-208.79M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-73.13M | $-0.65 | $-61.69M |
| Q1 '26 | 2026-03-31 | — | $-53.84M | $-0.48 | $-58.64M |
| Q4 '25 | 2025-12-31 | $0.00 | $-69.90M | $-0.75 | $-47.95M |
| Q3 '25 | 2025-09-30 | — | $-57.46M | $-0.65 | $-40.51M |
| Q2 '25 | 2025-06-30 | $4.01M | $-43.40M | $-0.50 | $-49.40M |
| Q1 '25 | 2025-03-31 | $2.93M | $-41.70M | $-0.52 | $-53.05M |
| Q4 '24 | 2024-12-31 | $2.74M | $-80.25M | $-1.28 | $-42.06M |
| Q3 '24 | 2024-09-30 | $2.91M | $-47.10M | $-0.78 | $-34.17M |
| Q2 '24 | 2024-06-30 | $2.36M | $-36.12M | $-0.60 | $-23.40M |
| Q1 '24 | 2024-03-31 | $1.03M | $-129.49M | $-2.51 | $-11.17M |
| Q4 '23 | 2023-12-31 | $3.83M | $-92.63M | $-4.22 | $-17.46M |
| Q3 '23 | 2023-09-30 | $3.56M | $-4.34M | $-0.36 | $-10.31M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.64
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-48.4%
ROA
-45.0%
Div Yield
0.00%
FCF Yield
-10.94%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.91B
as of 2026-11-06
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
17.28M
SI % of Float
17.08%
Days to Cover
12.16
Short Vol Ratio
82.3%
Free Float
101.21M
Float %
89.1%
Short interest 2026-10-15 • Short volume 2026-11-05 • Float 2026-08-14